References
1. Pseudolaric Acids from Pseudolarix kaempferi: B.N. Zhou, et al.; Planta Med. 47: 35 (1983). 2. The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid-A and -B and related derivatives: D.J. Pan, et al.; Planta Med. 56: 383 (1990) 3. Antifungal evaluation of pseudolaric acid B, a major constituent of Pseudolarix kaempferi: E. Li, et al.; J. Nat. Prod. 58: 57 (1995). 4. Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists: M.S. Jardat, et al.; Planta Med. 68: 667 (2002). 5. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect: W.F. Tan, et al.; Eur. J. Pharmacol. 499: 219 (2004). 6. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor1 alpha by promoting proteasome- mediated degradation: M.H. Li, et al.; Clin. Cancer Res. 10: 8266 (2004). 7. Pseudolaric acid B induces apoptosis through p53 and Bax/Bcl-2 pathways in human melanoma A375-S2 cells: X.F. Gong, et al.; Arch. Pharm. Res. 28: 68 (2005). 8. Pseudolaric acid B , a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo: V.K. Wong, et al.; Clin. Cancer Res. 11: 6002 (2005). 9. Effect of pseudolaric acid B on gastric cancer cells: inhibition of proliferation and induction of apoptosis: K.S. Li, et al.; World J. Gastroenterol. 11: 7555 (2005). 10. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin: Y.G. Tong, et al.; Mol. Pharmacol. 69: 1226 (2006)USBio References
No references available